HotStocks USA: Neues von der FDA-Front, -33% bei OCULAR THERAPEUTIX

Welche Aktien steigen vorbörslich besonders und welche verlieren deutlich? Die nachfolgende Übersicht zeigt die jeweiligen drei Tops und Flops aus dem NASDAQ 100 und dem S&P 500.

Zusätzlich können Sie nachfolgend die Meldungen entnehmen, welche die Kursbewegungen ausgelöst haben:

• Cara Therapeutics: today announced summary results from its Phase 1 safety and pharmacokinetic trial of Oral CR845 in chronic kidney disease (CKD) patients undergoing hemodialysis.
• Ceragon Networks: today announced that, during Q2, it has received orders totaling more than $9 million for its IP-20 Platform and related services from a tier 1 multiservice operator in India. This long-standing customer has placed orders totaling over $13 million during the first half of 2017 to increase 4G LTE network capacity and enhance subscriber experience across the nation.
• Fastenal: today announced its financial results for the quarter and six month period ended June 30, 2017.
• Ocular Therapeutix: announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its resubmission of a New Drug Application (NDA) for DEXTENZA™ (dexamethasone insert) 0.4mg for the treatment of ocular pain following ophthalmic surgery. The CRL states that the FDA has determined that it cannot approve the NDA in its present form.
• Alder BioPharmaceuticals: announced today that it intends to offer and sell, subject to market and other conditions, 12,500,000 shares of its common stock in an underwritten public offering.

Auf meinem Guidants-Desktop veröffentliche ich regelmäßig konkrete Handelsideen und setze diese in einem 20.000 EUR Echtgelddepot um!

Welche Basiswerte? Vollkommen egal, Hauptsache das Setup passt! Folgen Sie mir und holen Sie sich Anregungen für Ihren eigenen Trading-Ansatz!

Größte Gewinner:

Größte Verlierer: